Recently, a phase II trial investigated the clinical effect of combining durvalumab and olaparib plus paclitaxel (DOP) neoadjuvant chemotherapy in patients with high-risk stage II/III HER2-negative breast cancer [87]. The gene discussed is ERBB2; the disease is breast cancer.